Vincent Lo Re III, M.D., M.S.C.E.
Assistant Professor of Medicine
Department: Medicine
Graduate Group Affiliations
Contact information
Center for Clinical Epidemiology and Biostatistics
836 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104
836 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104
Office: 215-573-5964
Fax: 215-349-5111
Fax: 215-349-5111
Email:
vincentl@mail.med.upenn.edu
vincentl@mail.med.upenn.edu
Publications
Links
Search PubMed for articles
Center for Clinical Epidemiology and Biostatistics faculty webpage.
Search PubMed for articles
Center for Clinical Epidemiology and Biostatistics faculty webpage.
Education:
B.S. (Chemistry)
Georgetown University, 1992.
M.D. (Medicine)
University of Pennsylvania, 1997.
M.S.C.E. (Pharmacoepidemiology)
University of Pennsylvania, 2005.
Permanent linkB.S. (Chemistry)
Georgetown University, 1992.
M.D. (Medicine)
University of Pennsylvania, 1997.
M.S.C.E. (Pharmacoepidemiology)
University of Pennsylvania, 2005.
Description of Research Expertise
Research Interests- Hepatic and non-hepatic outcomes of chronic hepatitis B and C, particularly among patients with HIV infection
- Adherence to hepatitis C virus therapy
- Hepatotoxicity of medications
- Evaluation of clinical outcomes
- Population-based and administrative databases
Key Words
HIV/viral hepatitis coinfection; hepatitis B; hepatitis C; HIV/AIDS; epidemiology; clinical outcomes; pharmacoepidemiology
Description of Research
Dr. Lo Re’s research focuses on clinical outcomes of chronic viral hepatitis infection in HIV-infected patients. He is conducting epidemiologic studies to examine novel risk factors for decompensated cirrhosis among HIV/hepatitis C-coinfected patients and is working to develop and internally validate a clinical predictive index to stratify HIV/hepatitis C patients according to their risk of progression to hepatic decompensation. He has also examined the prevalence, risk factors, and clinical significance of occult hepatitis B virus infection in HIV-infected patients. Additional studies are examining non-hepatic outcomes of chronic viral hepatitis infection in HIV, particularly abnormalities in bone mineral density and fractures.
Dr. Lo Re also evaluates clinical outcomes of hepatitis therapy in the setting of HIV. Recent work has examined the incidence and risks factors for anemia and weight loss during hepatitis C therapy among HIV-infected patients. Another active area of research is adherence to combination pegylated interferon and ribavirin hepatitis C therapy, specifically examining the levels of adherence required for maximal hepatitis C suppression and risk factors for poor adherence to these therapies.
Methodologic interests include use of population-based databases for epidemiologic research, ascertainment and adjudication of clinical outcomes, and pharmacoepidemiology.
Selected Publications
Lo Re V III, Haynes K, Goldberg D, Forde KA, Carbonari DM, Leidl KBF, Hennessy S, Reddy KR, Pawloski PA, Daniel GW, Cheetham TC, Iyer A, Coughlin KO, Toh S, Boudreau DM, Cooper WO, Selvam N, Selvan MS, VanWormer JJ, Avigan MI, Houstoun M, Zornberg GL, Racoosin JA, Shoaibi A: Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration’s Mini-Sentinel Distributed Database. 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Montreal, Canada [Abstract 598]. August 25-28, 2013.Lo Re V III, Haynes K, Lewis JD, Carbonari DM, Leidl KBF, Forde KA, Goldberg D, Nezamzadeh MS, Reddy KR, Roy J, Sha D, Marks AR, De Boer J, Strom BL, Corley DA: Development and validation of an acute liver failure (ALF) risk prediction model for patients with drug-induced hepatitis (DIH). 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Montreal, Canada [Abstract 597]. August 25-28, 2013.
Haynes K, Nezamzadeh MS, Carbonari DM, Newcomb CW, Roy J, Cardillo S, Leidl KBF, Wood Ives J, DeVore S, Horne L, Blak B, Esposito D, Holick C, Van Staa T, Bhullar H, Strom BL, Lo Re V III : Factors associated with utilization of saxagliptin in the US and UK. 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Montreal, Canada [Abstract 939]. August 25-28, 2013.
Byrne DB, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V III: Chronic hepatitis B virus infection among U.S. Medicaid enrollees, 2000-2007. 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Montreal, Canada [Abstract 406]. August 25-28, 2013.
Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang KM, Lo Re V 3rd: Incidence and risk factors for incomplete hepatitis B virus DNA suppression in HIV/hepatitis B-coinfected patients receiving tenofovir-based antiretroviral therapy. J Viral Hepat Page: In Press, June 2013.
Amorosa VK, Aibana O, Shire NJ, Dorey-Stein Z, Ferrara T, Gilmore J, Kostman JR, Lo Re V 3rd: Willingness to undergo a repeat liver biopsy among HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients. J Clin Gastroenterol 47: 457-60, June 2013.
Lo Re V 3rd, Haynes K, Goldberg D, Forde KA, Carbonari DM, Leidl KBF, Hennessy S, Reddy KR, Pawloski PA, Daniel GW, Cheetham TC, Iyer A, Coughlin KO, Toh S, Boudreau DM, Cooper WO, Selvam N, Selvan MS, VanWormer JJ, Avigan MI, Houstoun M, Zornberg GL, Racoosin JA, Shoaibi A: Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration’s Mini-Sentinel Distributed Database. Pharmacepidemiol Drug Saf Page: In Press, May 2013.
Edelman EJ, Gordon K, Lo Re V III, Skanderson M, Fiellin DA, Justice AC: Acetaminophen receipt among HIV-infected patients with advanced hepatic fibrosis. Society of General Internal Medicine 36th Annual Meeting. Denver, CO [Abstract 1640956]. April 24 – 27, 2013.
Tetrault J, Tate J, Edelman EJ, Gordon A, Lo Re V III, Fiellin L, Bryant K, Justice A, Fiellin DA: Use and safety of buprenorphine in HIV-infected and uninfected opioid dependent patients. Society of General Internal Medicine 36th Annual Meeting. Denver, CO [Abstract 1640823]. April 24 – 27, 2013.
Lo Re V III, Kallan M, Tate J, Localio AR, Lim JK, Goetz MB, Butt AA, Brown ST, Kostman JR, Justice AC: Determinants of hepatic decompensation in ARV-treated HIV/HCV-coinfected patients. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA [Abstract 728]. March 3-6, 2013.